Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review

被引:11
作者
O'Kelly, Brendan [1 ]
Murtagh, Ross [1 ,2 ]
Lambert, John S. [1 ,2 ,3 ]
机构
[1] Mater Misericordia Univ Hosp, Infect Dis Dept, Dublin, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland
[3] Rotunda Matern Hosp, Infect Dis, Dublin, Ireland
关键词
HIV; pregnancy; therapeutic drug monitoring; antiretrovirals; breastfeeding; LOW-DOSE RITONAVIR; TREATMENT-NAIVE; RALTEGRAVIR PHARMACOKINETICS; EFAVIRENZ PHARMACOKINETICS; CLINICAL PHARMACOKINETICS; PROTEASE INHIBITORS; BREAST-MILK; LOPINAVIR; DARUNAVIR; PLASMA;
D O I
10.1097/FTD.0000000000000735
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To date, therapeutic drug monitoring (TDM) has played an important role in the management of pregnant HIV patients on highly active antiretroviral therapy. Historically, in pregnant women living with HIV, the third agent in triple therapy has been either non-nucleoside reverse transcriptase inhibitors or protease inhibitors (PIs). PIs have been the preferred agents because of their robustness from the perspective of viral resistance and the dominant drug class for the management of HIV during pregnancy for the previous decade. As with many drugs used during pregnancy, pharmacokinetic changes decrease exposure to these agents as the pregnancy progresses. This can lead to viral escape at the time of pregnancy and ultimately increase the risk of mother-to-child transmission (MTCT) of HIV. TDM has been well-established for this class of highly active antiretroviral therapy, and appropriate dose adjustment studies have been performed. At present, there is a shift from the traditional treatment paradigm in pregnancy to a new drug class, integrase strand transfer inhibitors (INSTIs). Although INSTIs are affected by pharmacokinetic changes during pregnancy, they do not harbor the same issues with viral escape as seen with PIs at birth and in general eliminate the need for boosting with additional agents like ritonavir (r) and cobicistat (c) [bar elvitegravir (EVG)] that can lead to interactions with treatment of other common infections in HIV, including tuberculosis. Furthermore, INSTIs are the most successful medication for rapidly reducing the viral load (VL) in HIV patients, a useful factor where VL may be unknown, or in late presenters. These merits make INSTIs the best choice in pregnancy, although their use has been hindered in recent years by a report of neural tube defects from a large African study with dolutegravir (DTG). New data from Botswana and Brazil indicate that this risk is less significant than previously reported, necessitating further data to shed light on this critical issue. Current international guidelines including DHHS, EACS, WHO, and BHIVA (for patients with VLs >100,000 copies/mL or late presenters) now recommend INSTIs as first-line agents. The role of TDM in INSTIs shifts to cases of insufficient viral suppression with standard adherence measures, cases of drug-drug interactions, or cases where EVG/c is continued throughout pregnancy, and thus remains an important aspect of HIV care in pregnancy.
引用
收藏
页码:229 / 244
页数:16
相关论文
共 88 条
  • [1] Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
    Acosta, EP
    Bardeguez, A
    Zorrilla, CD
    Van Dyke, R
    Hughes, MD
    Huang, S
    Pompeo, L
    Stek, AM
    Pitt, J
    Watts, DH
    Smith, E
    Jiménez, E
    Mofenson, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) : 430 - 436
  • [2] HIV Protease Inhibitors in Pregnancy Pharmacology and Clinical Use
    Andany, Nisha
    Loutfy, Mona R.
    [J]. DRUGS, 2013, 73 (03) : 229 - 247
  • [3] Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach
    Anderson, GD
    [J]. CLINICAL PHARMACOKINETICS, 2005, 44 (10) : 989 - 1008
  • [4] [Anonymous], 12 INT WORKSH CLIN P
  • [5] [Anonymous], 2016, WHO CONS GUID US ANT
  • [6] [Anonymous], 16 C RETR OPP INF MO
  • [7] [Anonymous], 2018, POT SAF ISS AFF WOM
  • [8] [Anonymous], 2015, 22 RETROVIRUSES OPPO
  • [9] [Anonymous], INT WORKSH CLIN PHAR
  • [10] Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)
    Arribas, Jose R.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2009, 4 (06) : 507 - 512